Hypophosphatasia (HPP), or "soft bone disease" is a rare genetic disorder that impacts bone and tooth development, leading to weak bones and other health complications. For years, enzyme replacement therapy has been the only effective treatment for HPP. This therapy involves injecting asfotase alfa, an enzyme that replaces the missing one in patients’ bodies. However, these injections must be given three to six times a week, which can be challenging for many patients. While t

A clinical trial for NGN-401, a gene therapy designed to treat Rett syndrome, recently faced a setback when a young participant experienced a severe immune reaction after receiving a high dose of the treatment. This reaction, called systemic hyperinflammatory syndrome, is a rare and dangerous immune response, causing her condition to become critical. As a result, high-dose treatments have been paused. Rett syndrome is a genetic disorder that primarily affects girls, leading t

A recent 6-year checkup on boys treated with gene therapy for cerebral adrenoleukodystrophy (CALD) reveals lasting benefits for most patients. CALD is a rare, severe brain disease that primarily affects young boys, often leading to a rapid decline in neurological function. In this follow-up, most patients showed stable brain function and minimal disabilities, showcasing the potential of gene therapy to bring hope to families facing this devastating diagnosis. A Closer Look at

Lenmeldy, a groundbreaking gene therapy developed by Orchard Therapeutics, has recently received FDA approval, making it the first and only treatment available for children with Metachromatic Leukodystrophy (MLD), a rare genetic disorder that severely affects the brain. Metachromatic Leukodystrophy is a rare lysosomal storage disorder caused by mutations in the ARSA and/or PSAP genes. These mutations result in the accumulation of sulfatide, leading to the degeneration of esse